Markets Share Share this article Copy linkX (Twitter)LinkedInFacebookEmail Short seller Culper bets against ether, BitM Markets Share Share this article Copy linkX (Twitter)LinkedInFacebookEmail Short seller Culper bets against ether, BitM

Short seller Culper bets against ether, Tom Lee's BitMine citing 'death spiral' risk

2026/03/06 05:14
5 min read
For feedback or concerns regarding this content, please contact us at [email protected]
Share
Share this article
Copy linkX (Twitter)LinkedInFacebookEmail

Short seller Culper bets against ether, BitMine citing 'death spiral' risk

The short seller firm said that Ethereum's native token is "impaired," leaving treasury firm BitMine holding the bag while co-founder Vitalik buterin is selling.

By Krisztian Sandor|Edited by Nikhilesh De
Mar 5, 2026, 9:14 p.m.
Make us preferred on Google
Thomas Lee, chairman of BitMine and CIO of Fundstrat, on the main stage during Consensus Hong Kong 2026 (David Paul Morris/Consensus)

What to know:

  • Short seller Culper Research disclosed a short position in ether and ETH-linked stocks including BitMine.
  • The firm argued Ethereum’s Fusaka upgrade weakened the tokenomics of the second-largest crypto by collapsing fee revenues and enabling spam transactions.
  • BitMine, a major ETH holder, has accumulated 4.4 million ETH and is estimated to be sitting on roughly $7.4 billion in unrealized losses.

Short seller Culper Research is betting against ether (ETH) and ETH-linked stocks such as BitMine (BMNR), arguing that the network’s economics deteriorated following Ethereum’s latest network upgrade.

The firm said in a Thursday report that the December 2025 upgrade dubbed Fusaka flooded the network with excess blockspace and has "impaired ETH tokenomics." That drove transaction fees sharply lower. Because validators earn part of their income from those fees, the drop has reduced staking yields.

That dynamic could create a negative feedback loop, the report said, where declining validator yields reduce staking demand and network security.

The report also highlighted that Ethereum co-founder Vitalik Buterin sold nearly 20,000 ETH, worth around $40 million at current prices, this year, citing data from blockchain sleuth Lookonchain.

"Vitalik is selling, while bulls like Tom Lee are clueless as to ETH’s new reality," the report said. "We’re with Vitalik."

The report pushes back on bullish claims from Lee, chairman of Ethereum-centric treasury firm BitMine, who has pointed to rising transaction counts and active addresses as evidence of stronger network fundamentals.

Culper said those metrics are misleading. Its analysis claimed a significant share of the activity surge stems from address poisoning attacks, a scam tactic where attackers send small transactions to trick users into copying malicious wallet addresses. Culper estimated Ethereum fees have dropped roughly 90% since the upgrade.

"By Lee’s own logic, if utility is NOT going up, then ETH is in a death spiral," the report said. "This is exactly what we believe is happening."

The short thesis also targeted BitMine (BMNR), one of the largest corporate buyers of ether.

Since July, the company has accumulated roughly 4.4 million ETH as part of its treasury strategy. With ether prices down significantly from recent highs, those holdings are estimated to be 45% underwater, with BitMine sitting on roughly $7.4 billion in unrealized losses, DropsTab data shows.

BitMine did not return a request for comment by press time.

Read more: Vitalik Buterin reveals his bold new plan to fix Ethereum’s scaling problem

Ethereum NewsBitmine

More For You

Pudgy Penguins: Challenging the Pokemon and Disney Legacy in the Global IP Race

CoinDesk Research looks into how Pudgy Penguins disrupts traditional toys market via a phygital model. With 2M+ units sold, they scale via global partnerships and events.

What to know:

  • Disrupting a Stagnant Market: Pudgy Penguins is utilizing a "Negative CAC" model to challenge the traditional $31.7B licensed toy industry by treating physical merchandise as a profitable user acquisition tool rather than just a final product.
View Full Report

More For You

CleanSpark sold 97% of February bitcoin production to fund AI pivot

The cash flow generated will support the bitcoin miner's expansion into AI and high-performance computing data centers.

What to know:

  • CleanSpark produced 568 BTC in February and sold 553 BTC, one of the highest production-to-sales ratios the company has reported, generating about $36.6 million in proceeds.
  • The company is expanding AI-ready infrastructure, including a 300 MW Texas campus, while holding 13,363 BTC in treasury, with 1,086 BTC pledged as collateral.
Read full story
Latest Crypto News

Ripple adds Coinbase crypto futures to its $3 trillion trading venue

Kraken's surprise Fed win may harken onslaught of crypto firms with narrow Fed access

U.S. judge freezes BlockFills assets in dispute over 70 bitcoin with creditor Dominion Capital

Son of U.S. government contractor, accused of stealing millions in seized crypto, arrested in France

Sanctions evasions using crypto increased by 700% in 2025: Chainalysis

CleanSpark sold 97% of February bitcoin production to fund AI pivot

Top Stories

Bitcoin pulls back to near $71,000 even as software sector soars

New York Stock Exchange owner values crypto exchange OKX at $25 billion in new partnership

Trump-backed American Bitcoin board members scoop up stock following earnings

Bitcoin traders, alert: The rally is nearing a two-year 'make or break' price zone

Andreessen Horowitz crypto arm said to seek $2 billion for fifth fund: Fortune

Bitcoin takes aim at $74,000. Surprisingly, the dollar's rallying too.

Market Opportunity
TOMCoin Logo
TOMCoin Price(TOM)
$0.00002371
$0.00002371$0.00002371
+0.29%
USD
TOMCoin (TOM) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09